Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $78,348.40 in Stock

Key Points

• Major shareholder Endurance (Cayman) Ltd Svf sold 12,844 shares of Vir Biotechnology stock for $78,348.40, reducing their stake by 0.08% to approximately 15.34 million shares.
• The stock of Vir Biotechnology is currently trading at $5.78, with a market capitalization of $802.96 million, after reporting disappointing quarterly earnings with a net margin down 60.5% year-over-year.
• Despite recent poor performance, several analysts including Bank of America and HC Wainwright have upgraded their ratings, with target prices increasing to as high as $15.00.

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) major shareholder Endurance (Cayman) Ltd Svf sold 12,844 shares of Vir Biotechnology stock in a transaction on Thursday, October 16th. The stock was sold at an average price of $6.10, for a total transaction of $78,348.40. Following the sale, the insider directly owned 15,340,494 shares of the company's stock, valued at $93,577,013.40. This represents a 0.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Wednesday, October 15th, Endurance (Cayman) Ltd Svf sold 16,671 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.07, for a total transaction of $101,192.97.
• On Friday, October 10th, Endurance (Cayman) Ltd Svf sold 2,300 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.08, for a total transaction of $13,984.00.
• On Thursday, October 9th, Endurance (Cayman) Ltd Svf sold 249,060 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.14, for a total transaction of $1,529,228.40.
• On Wednesday, October 8th, Endurance (Cayman) Ltd Svf sold 466,242 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.05, for a total transaction of $2,820,764.10.
• On Tuesday, October 7th, Endurance (Cayman) Ltd Svf sold 72,133 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.60, for a total transaction of $403,944.80.
• On Monday, October 6th, Endurance (Cayman) Ltd Svf sold 73,955 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.69, for a total transaction of $420,803.95.
• On Friday, October 3rd, Endurance (Cayman) Ltd Svf sold 450,342 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.56, for a total transaction of $2,503,901.52.

Vir Biotechnology Price Performance

Shares of Vir Biotechnology stock traded down $0.02 on Friday, hitting $5.78. The company had a trading volume of 1,071,614 shares, compared to its average volume of 1,537,480. The firm has a market capitalization of $802.96 million, a P/E ratio of -1.45 and a beta of 1.27. Vir Biotechnology, Inc. has a twelve month low of $4.16 and a twelve month high of $14.45. The stock has a 50-day moving average of $5.13 and a 200-day moving average of $5.28.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.08). The company had revenue of $1.21 million during the quarter, compared to analyst estimates of $2.38 million. Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. The firm's quarterly revenue was down 60.5% compared to the same quarter last year. During the same quarter last year, the company earned ($1.02) EPS. Equities analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on VIR. Bank of America upgraded shares of Vir Biotechnology from a "neutral" rating to a "buy" rating and upped their price target for the company from $12.00 to $14.00 in a report on Wednesday, August 27th. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of Vir Biotechnology in a research report on Monday, September 15th. Raymond James Financial assumed coverage on shares of Vir Biotechnology in a research report on Friday, July 11th. They set an "outperform" rating on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vir Biotechnology in a research report on Tuesday. Finally, Evercore ISI assumed coverage on shares of Vir Biotechnology in a research report on Wednesday, September 3rd. They set an "outperform" rating and a $12.00 price target on the stock. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.30.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. ARCH Venture Management LLC acquired a new position in Vir Biotechnology in the 2nd quarter worth about $65,100,000. Nordea Investment Management AB lifted its holdings in Vir Biotechnology by 403.7% during the 2nd quarter. Nordea Investment Management AB now owns 704,377 shares of the company's stock worth $3,677,000 after buying an additional 564,537 shares during the period. Clarius Group LLC lifted its holdings in Vir Biotechnology by 979.7% during the 2nd quarter. Clarius Group LLC now owns 617,535 shares of the company's stock worth $3,112,000 after buying an additional 560,342 shares during the period. Ensign Peak Advisors Inc lifted its holdings in Vir Biotechnology by 812.7% during the 2nd quarter. Ensign Peak Advisors Inc now owns 582,981 shares of the company's stock worth $2,938,000 after buying an additional 519,107 shares during the period. Finally, Nuveen LLC acquired a new position in Vir Biotechnology during the 1st quarter worth about $2,324,000. 65.32% of the stock is currently owned by institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.